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Cholangiocarcinoma (CCA) comprises a heterogeneous group of
cancers with pathologic features of biliary tract differentiation,
and is presumed to arise from the intra- or extrahepatic biliary
tract. Two recent papers suggest these cancers may also arise
directly from transdifferentiation of hepatocytes [1,2]. Gallblad-
der cancer is distinct from cholangiocarcinoma in epidemiology,
pathobiology, clinical presentation and management, and should
be considered a different form of biliary tract cancer [3]. On the
basis of its anatomical origin, CCA is best classiﬁed anatomically
as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA) CCA [4].
The incidence of iCCA appears to be increasing and may be as
high as 2.1 per 100,000 person years in Western Countries [5].
iCCA may occur in patients with normal liver or with underlying
liver disease, and in either clinical context usually is classiﬁed
pathologically as an adenocarcinoma, although mixed hepatocel-
lular – cholangiocarcinomas also occur, especially in chronic liver
disease [6].
Given the increasing incidence of this complex and fatal dis-
ease, the growing recognition of iCCA as a distinct cancer, and
the large number of recent publications on this disease, the Inter-
national Liver Cancer Association (ILCA) governing board noted it
was both timely and topical to develop practice guidelines on
iCCA. These guidelines are largely based on a consensus of a mul-
tidisciplinary, geographically diverse writing committee using a
data-supported approach, and subsequently reviewed by a sepa-
rate Practice Guidelines committee of ILCA. The ILCA guidelinesJournal of Hepatology 20
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Open access under CC BY-NC-ND license.committee employed an extensive PubMed search to broadly
canvas the existing literature. Each author then wrote different
sections of the manuscript relative to their expertise. All authors
then reviewed and edited the manuscript to ensure objectivity
and evidence-based recommendations. Finally an ILCA oversight
committee reviewed the document, provided recommendations,
and then additional edits were made to the document. Thus, a
two-tiered integrated and interactive process was employed to
generate the guidelines. These recommendations suggest pre-
ferred approaches to the diagnostic and therapeutic aspects of
care, and are intended to be ﬂexible, in contrast to standards of
care, which should be supported by robust evidence-based data.
Thus, the guidelines have two principal goals: (1) to provide
physicians with pragmatic clinical recommendations; and (2) to
identify areas of interest for future research, including
suggestions for conducting clinical trials. The evidence and
recommendations in these guidelines have been graded
according to the Grading of Recommendations Assessment
Development and Evaluation (GRADE) system, Table 1 [7]. The
GRADE system classiﬁes the evidence as high, moderate, low or
very low quality. The strength of recommendation is either
strong or weak based on the quality of underlying evidence,
outcomes, and cost.Epidemiology & risk factors
The incidence of cholangiocarcinoma varies substantially world-
wide with the highest known rates in Northeast Thailand (>80
per 100,000 population) and much lower rates in the Western
world, for example Canada (0.3 per 100,000) (Fig. 1) [8]. iCCA is
the second most common primary liver cancer in humans, after
hepatocellular carcinoma (HCC). Although the frequency of iCCA
worldwide is considerably less than HCC, of note, several recent
studies from around the world have reported rapidly rising rates
of iCCA over the last few decades [9–11].14 vol. 60 j 1268–1289
Table 1. Grading of evidence and recommendations (adapted from GRADE system) [7].
Evidence quality Notes Grading
High A
Moderate
change the estimate
Further research is very unlikely to change our confidence in the estimate of effect
Further research is very likely to have an important impact on our confidence in the estimate of effect and
Factors influencing the strength of the recommendation included the quality of the evidence, presumed 
Further research is likely to have an important impact on our confidence in the estimate of effect and may B
Low
is likely to change the estimate. Any change of estimate is uncertain
C
Recommendation Notes Grading
Strong 
recommendation 
warranted
patient-important outcomes, and cost
1
Weak Variability in preferences and values, or more uncertainty: more likely a weak recommendation is 
warranted. 
Recommendation is made with less certainty, higher cost or resource consumption
2
Fig. 1. Incidence of cholangiocarcinoma worldwide where reported.
JOURNAL OF HEPATOLOGYTrends in iCCA rates worldwide
An increase in mortality rates from iCCA was concomitantly
reported in studies from the US and the UK [12,13]. The study
from the UK analyzed age standardized mortality rates (ASMR)
per 100,000 population for hepatopancreatobiliary (HPB) tumors
[12]. Between 1968 and 1996, there was a 15-fold increase in age
speciﬁc mortality rates (ASpMR) from 0.1 to 1.5 per 100,000 pop-
ulation in ages 45 and above in both sexes. Since the mid-1990s,
iCCA has become the most common cause of death from a pri-
mary liver tumor in England and Wales, overtaking HCC. Similar
trends were found in incidence rates of this cancer in England
and Wales [14]. A study from the US also reported a marked rise
in both incidence and mortality rates from iCCA between 1973
and 1997, with an estimated annual percent change (EAPC) of
9.1% and 9.4% respectively [13]. Age-adjusted incidence rates ofJournal of Hepatology 2014iCCA in the US increased by 165% from 0.3 per 100,000 in
1975–1979 to 0.9 per 100,000 in 1995–1999 [10,11]. More recent
studies from Italy and Germany also reported rises in iCCA. In
Italy iCCA mortality rates increased from 0.2 to 5.9 per million
between 1980 and 2003 [15] and in Germany iCCA mortality
more than tripled between 1998 and 2008 [16]. Incidence rates
of iCCA have also recently increased in Korea, with an annual per-
cent change (APC) of 8% in males and 11% in females, between
1999 and 2005 [17].
Two studies examining international time trends in mortality
rates using the World Health Organization’s (WHO) database
found that ASMR for iCCA had risen in almost all countries across
all continents, albeit at different rates [18,19]. The average global
estimated annual percent change (EAPC) in ASMR for males was
6.9 ± 1.5, and for females 5.1 ± 1.0 [19]. In contrast to the afore-
mentioned data, in Denmark between 1978 and 2002, incidencevol. 60 j 1268–1289 1269
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rates of iCCA decreased from 1.3 to 0.5 per 100,000 people [20].
Why iCCA has decreased in Denmark in contrast to other coun-
tries is unknown.
Ethnic differences in iCCA rates
The reports so far described have found similar trends in iCCA
rates in both sexes, with a slight male predominance overall
(male to female ratio 1.2–1.5:1) [21]. Two studies, both from
the US, have examined trends in iCCA rates based on ethnicity
within geographically deﬁned regions [22,23]. Both investiga-
tions, using data from the US Surveillance, Epidemiology, and
End Results (SEER) database, noted signiﬁcant racial and ethnic
differences in iCCA rates. The age-adjusted prevalence of iCCA
per 100,000 for males and females, respectively, for all races
was 0.9 and 0.6; for Whites, 0.9 and 0.6; for Blacks, 0.5 and 0.2;
and for Asian/Paciﬁc Islanders was 1.3 and 0.8 [22,23]. iCCA prev-
alence was highest in Hispanics (1.2 per 100 000), and in contrast
to the general male predominance, the prevalence among His-
panics was higher in females compared with males (1.5 vs. 0.9
per 100,000). Age-adjusted mortality rates for males and females
were higher for American Indian/Alaska Native (1.3 per 100,000)
and Asian Paciﬁc groups (1.4 per 100,000) than for either Whites
(0.8 per 100,000) or Blacks (0.7 per 100,000) [22]. However, mor-
tality rates increased by over 3.5% per year for all ethnic groups
except for American Indian/Paciﬁc Islanders, in whom mortality
rates decreased by 0.2% annually. The increase in mortality rates
was greatest for Hispanic women aged between 40 and 49 years.
In a separate study, iCCA incidence rates were similar for Black
and White men (0.9/100,000), but higher for White women
(0.6/100,000) compared to Black women (0.4/100,000) [23].
Although iCCA incidence increased among all groups, approxi-
mately doubling between 1976 and 2000, the increase was great-
est for Black men (138.5%), followed by White men (124.4%),
White women (111.1%), and Black women (85.7%) [23].
Are the reported rates of changing CC incidence accurate?
There is an evolving discussion in the literature about whether
iCCA incidence is genuinely increasing. The possibility that rising
iCCA rates may reﬂect improved detection, for example due to
improvements in diagnostic techniques over the past few dec-
ades, has rarely been investigated. One US study addressed this
question by examining SEER data between 1975 and 1999
[10,11]. iCCA incidence increased by 165%, during which time
no signiﬁcant changes were found in the proportion of patients
with unstaged cancer, localized cancer, microscopic conﬁrmation,
or with tumor size <5 cm, suggesting a true increase in iCCA
rather than earlier or improved diagnosis [10,11]. Further studies
looking at this issue are warranted, particularly given that CCA
can be notoriously difﬁcult to accurately diagnose [24]. When
iCCA presents at an advanced stage, which is common, it can be
impossible to determine the anatomical origin, and the histolog-
ical sub-type, which can result in misclassiﬁcation as a non hepa-
tobiliary upper gastrointestinal tract adenocarcinomas [21]. A
signiﬁcant issue is the lack of histopathological conﬁrmation in
a substantial percentage of iCCA cases in most cancer registries
worldwide, which makes it impossible to deﬁnitively establish
the true epidemiological behavior of iCCA [25].
Another confounding factor in assessing CCA epidemiology is
that of potential misclassiﬁcation under serially evolving editions1270 Journal of Hepatology 2014of the World Health Organization’s (WHO) International Classiﬁ-
cation of Disease (ICD) coding systems. Alongside the main ICD
coding system is the ICD coding system for Oncology (ICD-O),
which was introduced in 1979 and assigns two codes dependent
upon a tumor’s anatomical topography and morphology (based
on histology) [26]. Thus there are separate codes for topography
and histology. Both ICD and ICD-O are updated every few years
and codes are altered. Furthermore, these changes are adopted
by different countries’ cancer registries at different times. There
is increasing consensus that iCCA, pCCA, and dCCA are three dis-
tinct entities due to their differing epidemiology, pathobiology,
clinical presentations, and management [4]. The most common
type of CCA encountered in clinical practice is perihilar, histori-
cally referred to as a Klatskin tumor [27]; the deﬁnition of pCCA
includes tumors above the junction of the cystic duct up to and
including the second biliary branches of the right and left bile
ducts that reside within the hepatic parenchyma [4,28]. However,
CCA are only coded as either intra- or extrahepatic and a separate
ICD topography code for perihilar tumors does not exist. pCCA are
topographically extrahepatic and should have historically been
coded as such [24]. However, the ﬁrst edition of the ICD for
Oncology (ICD-O) did not specify whether pCCA should be classi-
ﬁed as intra- or extrahepatic. The second edition of ICD-O
assigned Klatskin tumors a unique histology code for the ﬁrst
time, but this was cross-referenced to the topography code for
intrahepatic (IHBD) rather than extrahepatic bile duct tumors
(EHBD). Under the third and current edition of ICD-O-3, Klatskin
tumors can be cross-referenced to either IHBD or EHBD. Thus,
hilar/Klatskin tumors may have been misclassiﬁed under all ver-
sions of the ICD-O [24,29].
The impact of this misclassiﬁcation on site-speciﬁc CCA inci-
dence rates was examined using US SEER data [29]. Between
1992 and 2000, when SEER used ICD-O-2, 91% of pCCA were
incorrectly coded as iCCA, resulting in an overestimation of iCCA
by 13%. However, they found that the overall proportion of
tumors classiﬁed as Klatskin or pCCA in the SEER database was
low, at only 8%. This was a surprising ﬁnding given that in pub-
lished studies, as well as clinical experience, pCCA tumors
account for the majority of all CCA [27]. A study of CCA incidence
in East and South-eastern Asia also found that the proportion of
Klatskin/pCCA tumors among CCA was less than that reported
in clinical settings [30]. Furthermore, coding practices for pCCA
tumors differed between cancer registries in Asia.
A more recent study compared the impact of ICD coding
changes on CCA incidence rates between 1990 and 2008 in
England, Wales, and the US [24]. Coding practices by all national
cancer registries in England and Wales were also assessed via
questionnaire [24]. In the US, the age standardized incidence rate
(ASIR) for iCCA rose from 0.6/100,000 to 0.9 between 1990 and
2001, then fell sharply before plateauing at 0.6 by 2007. ASIR
for extrahepatic bile duct tumors remained stable at around
0.8/100,000 population until 2001, then increased to 1.0 by
2007. In England and Wales, between 1995 and 2008, the vast
majority of pCCA tumors were coded as intrahepatic. This was
also the case in the US until 2001, when the situation was
reversed and subsequently most pCCA tumors were coded as
extrahepatic. Of note, US trends in intra- and extrahepatic tumors
began to reverse when the switch from ICD-O-2 to ICD-O-3
occurred in 2001. In the UK, the switch to ICD-O-3 only occurred
in 2008, the end of the study period. Furthermore, in England and
Wales, only 1% of CCA were reportedly pCCA, which is clearly avol. 60 j 1268–1289
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massive underestimation. Cancer registries in England and Wales
stated they would not code a CCA described as hilar with the des-
ignated Klatskin histology code, even though they are the same
entity, as the term hilar is not in the ICD classiﬁcation. In the
UK, the term hilar is used rather than Klatskin and most cancer
registries conﬁrmed that if the tumor site is unspeciﬁed, or sim-
ply says hilar or perihilar, the CCA would be coded as intrahe-
patic. Thus coding misclassiﬁcation is likely to have skewed
CCA registration to an intrahepatic site, thereby contributing to
previously reported rises in iCCA, at least in England and Wales
and likely in other countries [24]. Given CCA is relatively uncom-
mon in most countries, subtle misclassiﬁcations can substantially
affect reported rates [21].
In conclusion, close surveillance of international incidence
trends for all hepatobiliary tumors is recommended. An accurate
and consistent classiﬁcation practice for CCA is needed interna-
tionally considering the potential misclassiﬁcation of pCCA. We
suggest bile duct cancers could be sub-classiﬁed as iCCA, pCCA,
or dCCA with the term Klatskin being omitted altogether
[4,31,32]. The terms intrahepatic vs. extrahepatic are unhelpful
in this situation. Importantly, however CCA are classiﬁed, their
overall incidence seems to be increasing and the reasons for this
need to be investigated [24].
Recommendations 1
Recommendations
Suggestions for future studies
• CCA should be sub-classified as intrahepatic (iCCA), 
perihilar (pCCA), or distal (dCCA) where iCCA arises 
within the liver parenchyma. The terms Klatskin and 
extrahepatic are discouraged
Recommendation A1 
• Overall the incidence of iCCA seems to be increasing 
globally and the reasons for this need to be further 
investigatedRisk factors for iCCA
Cholangiocarcinogenesis is likely to be a multifactorial process
[33]. Signiﬁcant geographical and ethnic variations in the epide-
miology of CCA, globally and within the same geographical
regions, likely reﬂect differences in genetic, environmental and/
or cultural predispositions to the disease. Several risk factors
for CCA have been identiﬁed, however in the vast majority of
cases the disease is sporadic and known or suspected risk factors
are not present [9,21]. Unfortunately, studies examining potential
risk factors often do not differentiate between iCCA, pCCA or
dCCA and so the effects of different risk factors on CCA sub-types
are unclear [21]. Long established risk factors for CCA, such as
hepatobiliary ﬂukes, primary sclerosing cholangitis (PSC), biliary
tract cysts, hepatolithiasis and toxins are associated with chronic
biliary inﬂammation and increased cellular turnover [33]. More
recently recognized risk factors for iCCA are similar to those
known for HCC, such as cirrhosis, chronic hepatitis B and C, obes-
ity, diabetes, and alcohol [34]. However, the prevalence of these
risk factors is much lower for iCCA than for HCC. Suspected riskJournal of Hepatology 2014factors include inﬂammatory bowel disease, smoking, and
genetic polymorphisms. Many known risk factors for CCA such
as PSC, are associated with pCCA or dCCA, and will not be
reviewed here.
In regions of the world with highest CCA incidence, such as
Northeastern Thailand, where CCA is the most common cancer
and a major cause of mortality, the hepatobiliary ﬂukes Opisthor-
chis viverrini and Clonorchis sinensis are strongly associated with
the development of CCA. In 2009, these ﬂukes were classiﬁed as
group 1 human carcinogens for CCA by the WHO’s International
Agency for Research on Cancer. Human infection occurs via eat-
ing raw/undercooked freshwater ﬁsh; subsequently, the ﬂukes
inhabit the biliary tree leading to chronic irritation [35]. Several
case-control studies and a recent meta-analysis have shown a
strong association between liver ﬂukes and CCA, with odds ratios
(OR) of up to 27 [36]. Consumption of nitrosamine-contaminated
food may be an additional risk factor [37,38]. Apparently approx-
imately 40% of CCA associated with ﬂukes are iCCA.
Choledochal cystic diseases, such as Caroli’s disease, are
uncommon inherited abnormalities of the pancreatobiliary ducts
which result in reﬂux of pancreatic enzymes, cholestasis, and bil-
iary inﬂammation [39]. These diseases, which are more common
in Asian than Western countries, are strongly associated with
CCA, with an overall lifetime risk ranging from 5% to 30%
[39,40]. Compared to Western peoples, Asians have a higher
prevalence of choledochal cysts and also a higher incidence of
CCA, up to 18% compared to 5% lifetime risk of CCA [39,41,42].
Types I (solitary, extrahepatic) and IV (intra- plus extrahepatic)
bile-duct cysts have the greatest predisposition to CCA [39].
CCA incidence in these patients increases with age, the average
age at CCA diagnosis is 32 years [39]. A recent Korean case-con-
trol study conﬁrmed a strong association between bile duct cysts
and iCCA, with an OR of 10.7 [43]. A US SEER-based study
reported strong associations between bile duct cysts and
increased risk of iCCA (OR 36.9) and extrahepatic CCA (OR 47.1)
[44].
Calculi in the biliary tree, with or without concomitant para-
site infection, are a known risk factor for CCA. For reasons which
are unknown, hepatolithiasis is far more common in Southeast
Asia than the West (up to 20% in countries such as Thailand, com-
pared to 2% in the US) [21]. Case-control studies have found high
ORs for developing iCCA with hepatolithiasis, up to 50 in Korea
[43], 6 in China [45], and 7 in Italy [46]. In a hospital based
case-control study from China; smoking, a family history of can-
cer, and a greater than 10 year duration of symptoms were inde-
pendent risk factors for iCCA development in patients with
hepatolithiasis [47].
Case-control and cohort studies from Denmark, Japan, US, and
Korea have reported cirrhosis, of any aetiology, as an independent
risk factor for iCCA with risk estimates ranging between 5 and 14
[43,44,48–50]. A recent meta-analysis of seven case-control stud-
ies, including data on almost 400,000 patients, found that cirrho-
sis was associated with an overall OR of 23 for iCCA [34]. A series
of recent case-control studies from Asia, the US and Europe have
reported a strong association between chronic viral hepatitis and
iCCA [36,43–46,50–53]. However, studies report conﬂicting ﬁnd-
ings as to whether HBV or HCV or both viruses were associated
with CCA. Risk estimates for HBV as a risk factor for iCCA varied
between 2.3 (Korea) [43,53] and 28.6 (US) [53]. In a recent meta-
analysis, eight case-control studies investigating HBV as a risk
factor for iCCA, including data from 1991 to 2008 andvol. 60 j 1268–1289 1271
Guidelines
encompassing a total study population of almost 295,000
patients were selected [34]. The meta-analysis indicated that
overall, HBV was associated with iCCA with a combined OR of
5.5. There were no signiﬁcant differences between studies from
Eastern or Western countries. A retrospective case-control study
from Taiwan reported 38% of all iCCA were Hepatitis B surface
antigen positive (OR 5.0) and 13% were seropositive for HCV
(OR 2.7) [54]. The mean age of iCCA patients with HBV was
9 years younger than iCCA patients with HCV. Similarly, a recent
study from China found that, compared to HBV seronegative
patients with iCCA, HBV seropositive iCCA patients were younger,
more commonly male, and had a higher incidence of raised
serum alpha-fetoprotein level and cirrhosis [55]. Regarding HCV
as a risk factor for iCCA, risk estimates in individual studies varied
between 2.6 (US) [51] and 9.7 (Italy) [46]. In a meta-analysis HCV
was associated with iCCA, with an OR of 4.8 [34].
Obesity is increasingly linked to several cancers. In a UK study,
a body mass index of >30 was signiﬁcantly associated with biliary
tract cancer, but this included all CCA types as well as gallbladder
cancer [56]. A recent US study of SEER data between 1993 and
2005 reported that metabolic syndrome was signiﬁcantly associ-
ated with an increased risk of iCCA (OR 1.6) [57]. A combined
analysis of two US and one Danish study, investigating obesity
as a risk factor for iCCA, revealed an overall OR of 1.6 [34]. Indi-
vidual studies report conﬂicting results regarding diabetes as a
risk factor for iCCA. Three large population based case-control
studies, two US [44,48], and one UK [56], reported a signiﬁcant
positive association between diabetes and CCA, with risk esti-
mates between 1.5 and 2.0. Conversely, a population based
case-control study in Denmark [44], and three hospital-based
studies from China [45], Japan [50], and the US [53] did not show
a signiﬁcant association. However, a meta-analysis found diabe-
tes was associated with an overall OR of 1.9 for iCCA [34].
Individual case-control and cohort studies, including those
already referenced, have reported contrasting ﬁndings regarding
an association between alcohol use and CCA. In the recent meta-
analysis alcohol excess was associated with an overall OR of 2.8
for iCCA [34]. In contrast to alcohol, the data linking smoking to
iCCA are either negative or demonstrate a weak association
[21]. A meta-analysis of these eight studies estimated an overall
OR of 1.3 with conﬁdence intervals of 0.95–1.8 [34]. However,
signiﬁcant heterogeneity between studies was noted, as well as
inconsistencies regarding parameters of smoking frequency orTable 2. Host genetic polymorphism associated with cholangiocarcinoma.
Gene product Abbreviat
5,10-Methylenetetrahydrofolate reductase MTHFR
Thymidylate synthase TS
Glutathione S-transferases GST01
Multidrug resistance-associated protein 2 MRP2/AB
ATP8B1 FIC1
Natural killer cell receptor in PSC patients NKG2D
X-ray repair cross-complementing group 1 XRCC1
Prostaglandin-endoperoxide synthase 2/cyclooxygenase-2 PTGS2, C
Heterozygosity for the alpha1-antitrypsin Z allele
1272 Journal of Hepatology 2014duration. Further data are required to clarify if smoking is a gen-
uine risk factor for iCCA.
Host genetic polymorphisms
Given that only a minority of people with any of the established
risk factors for CCA get the disease, and given the signiﬁcant eth-
nic and geographical variations in CCA incidence, it is likely that
host genetic factors play a role in CCA predisposition [33]. There
is some evidence for this from several case-control studies, which
suggest that variations in genes coding for a number of enzyme
systems may be associated with increased CCA risk (Table 2).
These studies have involved relatively small numbers, with CCA
cases ranging between 50 and 200, and CCA sub-types are usually
unspeciﬁed. Larger genetic studies are required to shed further
light on this important area.Recommendations 2
Recommendations
• iCCA has similar risk factors to HCC, including cirrhosis, 
chronic viral hepatitis, alcohol excess, diabetes, and 
obesity, which suggests common pathobiological 
pathways to all primary liver parenchymal tumors. 
Recommendation A1
• Further investigations regarding genetic polymorphisms 
and the risk of iCCA are recommended
Suggestions for future studiesMolecular pathogenesis
Overview
The molecular pathogenesis of iCCA is a complex issue involving
several signal transduction pathways and molecular events
(Fig. 2) [58,59]. iCCA likely results frommalignant transformation
of cholangiocytes, and in a subset of cases from progenitor cells,
although this paradigm has been challenged [1,2]. Recent dataion Protein function [Ref.]
Involved in folate metabolism and DNA methylation [223]
Associated with DNA repair
Family of detoxification enzymes
[223]
[224]
C2 Biliary transporter involved in clearing biliary toxins
Biliary transporter involved in trafficking
[225]
phosphotidylserine in cellular membranes
[226]
Role in activating NK cells, key for tumor 
surveillance
[227]
Involved in DNA repair
An inflammatory mediator
pro-inflammatory enzymes
[228]
OX-2 [229]
A protease inhibitor which protects against [230]
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Fig. 2. Signaling pathways and molecular therapies in intrahepatic cholangiocarcinoma. Adapted by permission from McMillan Publishers Ltd.: Oncogene [59],
Copyright (2013).
JOURNAL OF HEPATOLOGYindicate common genomic traits between iCCA and HCC, support-
ing the hypothesis of common cell ancestors in speciﬁc molecular
subclasses: (1) Transcriptome analysis suggests that the poor
prognostic subclass of iCCA shares genomic traits and signatures
of poor prognosis of HCC [58,60,61], which are associated with
stem-like molecular signatures [62,63]; (2) iCCA and HCC share
common copy number variations including gains (1q, 8q, and
17q) and losses (4q, 8p, 13q, and 17p) of arms and high-level
ampliﬁcations of 11q 13 [58,60,64]; and (3) iCCA shares domi-
nant risk factors associated with HCC development, including cir-
rhosis, HBV and HCV infections, and metabolic syndrome due to
diabetes and/or obesity [34,57].Journal of Hepatology 2014Genetic alterations in iCCA
A discrete number of mutations, chromosomal aberrations,
deregulated signaling pathways, and epigenetic changes have
been reported in iCCA.Mutations
Activating mutations of KRAS represent one of the most frequent
genetic mutations found in iCCA (5–54%) [58,60,65,66]. KRAS
gene has been shown to be a bona ﬁde oncogene inducing
iCCA in genetically engineered mouse models [67], and thesevol. 60 j 1268–1289 1273
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mutations have been associated with a more aggressive pheno-
type [60]. Loss-of-function mutations of TP53 occur in 20% of
cases, and have been proven oncogenic in experimental models
of iCCA [68,69]. BRAF, NRAS, PI3K, EGFR, and MET mutations are
rare events involving <5% of cases [58,60,70]. Recently, mutations
in isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) have been
identiﬁed in 10–23% of 340 iCCA [71,72]. These mutations co-
occurred with TP53 mutations and were associated with DNA
hypermethylation [72]. There is no reported study assessing
whole-genome sequencing in iCCA, and the sole data available
include eight cases of liver ﬂuke-related CCAs [73].
Copy number variations
There are only a few studies reporting chromosomal imbalances
in iCCA [58,74–78]. Five studies investigated copy number varia-
tions (CNV) performing comparative genomic hybridization
(CGH) in 98 patients [74–78] and one study used single nucleo-
tide polymorphism (SNP) arrays in 149 patients [58]. The main
ﬁndings of these studies included frequent chromosomal gains
on 8q, 17q, and 20q and deletions on 3p (60%), 4q, 9p, and 17p.
The one study using SNP array technology [58] identiﬁed high-
level ampliﬁcations (e.g., 1p31, 11q13) and focal deletions (e.g.,
9p21, 14q22) in 4–12% of cases, pinpointing candidate regions
harboring novel oncogenes and oncosuppressors.
Protein fusions
Fusions including the kinase domain of FGFR2 have been recently
reported [79]. This observation has been conﬁrmed by a recent
study from Japan coupled with functional studies in cell culture
[80]. Moreover, several groups have similar observations (unpub-
lished observations).
Epigenome changes
Epigenetic silencing through promoter hypermethylation along
with miRNA deregulation have been described in a few studies
[63,81]. Single-gene studies deﬁne common alterations in iCCA:
hypermethylation of p16INK4A in 18–83% of cases [82], SOCS-3 in
88% [83], RASSF1A in 49% [75], and p14ARF in 25% [84]. At the
same time, a cluster of 38 miRNAs was identiﬁed as markedly
deregulated in iCCA and some of themwere associated with aber-
rant signaling pathways (e.g., HGF/MET, IL-6/STAT-3) [81].
Amongst all miRNA deregulated, a link between miR-200c signal-
ing, NCAM activation/stem cell gene expression trait and poor
prognosis has been proposed [63]. Recent papers have been pub-
lished assessing mutations in various populations with iCCA
[73,85]. These studies highlight the role of chromatin modiﬁers
especially BAP1 in the genetic pathogenesis of this disease
[85,86]. Thus, epigenetic alterations appear to play a dominant
role in this disease.
Signaling pathways activated in iCCA
Several pathways have been found to be deregulated in iCCA,
including inﬂammatory, cell cycle, and growth factor signaling
pathways (Fig. 2). Although they contain potential drivers of car-
cinogenesis, to date no oncogenic addiction loop has been
documented.1274 Journal of Hepatology 2014IL6-STAT3 pathway
Inﬂammation has been closely linked to an increased risk of iCCA.
Overall, JAK/STAT signaling activation occurs in 50% of iCCA, and
may affect more than 70% of the iCCA inﬂammation subclass [58].
In particular, IL-6 is an important oncogenic player in the growth
of malignant cholangiocytes [83,87,88] and its over-expression
may be a consequence of the epigenetic silencing of SOCS-3,
the inhibitor of cytokine signaling [83,89].EGFR signaling
Members of the EGFR family have been implicated in iCCA path-
ogenesis, and over-expression of EGFR (10–32%) and HER-2/neu
have been reported in iCCA patients [90–92]. Ampliﬁcations
and/or mutations of EGFR or HER-2 are very rare in iCCA. Aber-
rant EGFR phosphorylation activates MAPK/ERK and p38, which
in turn increases COX-2.Hepatocyte growth factor/Met signaling
C-Met, the tyrosine kinase receptor for hepatocyte growth factor
(HGF), is over-expressed in iCCA (12–58%) [93,94]. Cross-talk
between activation of EGFR family members, particularly HER-
2, with c-Met pathways has been described in experimental mod-
els and in human studies [94,95].Molecular classiﬁcation of iCCA
Molecular stratiﬁcation can be based on biomarkers as predictors
of response to targeted drugs or biomarkers as prognostic factors.
Few molecular subclasses have been adopted in management
guidelines, and they are typically based upon biomarker predic-
tors of treatment response. This is the case of ampliﬁcation of
Her2/neu and responders to trastuzumab in breast cancer [96],
EGFR mutational status or ALK status and response to erlotinib
and crizotinib, respectively, in non-small cell lung cancer
[97,98], and B-RAF mutations to identify responders to B-RAF
inhibitors in melanoma [99]. No such case has been described
in iCCA.
Recent advancements have been made in deﬁning molecular
subclasses in iCCA based on whole-transcriptome analysis and
other biological parameters [58–61,63,100,101]. The ﬁrst com-
prehensive study included 104 cholangiocarcinoma cases –
including iCCA, pCCA, and dCCA – and described two molecular
subclasses, one of which was associated with poor prognosis and
activation of receptor tyrosine kinases (RTKs), including EGFR,
ERBB2, and MET [60]. An integrative genomic study of 149 iCCA
identiﬁed two molecular subgroups, inﬂammation and prolifera-
tion, with distinct genomic proﬁles and clinical outcomes
[58,59]. The inﬂammation subclass (40%) showed an enrichment
of inﬂammation and cytokine pathway signatures, over-expres-
sion of IL6, IL10, and IL17 and constitutive activation of STAT3.
The proliferation subclass (60%) was characterized by enrich-
ment of activated oncogenic pathways including RAS/MAPK
and MET, high-level DNA ampliﬁcations at 11q13, deletions at
14q22.1 and signatures of poor clinical outcomes. Further inde-
pendent validation of iCCA subclasses is needed prior to adop-
tion as stratiﬁcation factors in iCCA guidelines.vol. 60 j 1268–1289
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Recommendations 3
Recommendations
• Signaling pathways, drivers of carcinogenesis, and 
potential targets for therapies in iCCA include KRAS/
MAPK, EGFR, IL-6/STAT, IDH1/2, FGFR2 and MET 
signaling. No oncogenic addiction loops have been 
described so far
Recommendation C1
• Molecular classification of iCCA based on gene 
signatures or molecular abnormalities is not ready for 
clinical application
Recommendation C1
• Future studies should focus on integrative genomic 
analysis studies combining genetic alterations with 
pathway identification, validating the use of genetic 
biomarkers to direct therapy, and further genetically 
stratifying patients with iCCA
Suggestions for future studiesClinical diagnosis of iCCA
Clinical presentation
The clinical presentation of iCC is non-speciﬁc and insufﬁcient to
establish a diagnosis. Patients with early stage disease are usually
asymptomatic. At more advanced stages, patients may present
with weight loss, malaise, abdominal discomfort, jaundice, hepato-
megaly, or a palpable abdominal mass. Biliary tract obstruction
occurs infrequently with iCCA. Tumor-related fever may rarely
occur, although night sweats are common in advanced disease.
Increased cholestasis and a declining performance status may
occur in patients who develop CCA. CCA should be considered in
patients with underlying hepatolithiasis or PSC with worsening
performance status, unexplained loss of weight, or failure to thrive.
Pathologic diagnosis
A pathological diagnosis of iCCA is based on the WHO classiﬁca-
tion of biliary tract cancer showing an adenocarcinoma or mucin-
ous carcinoma [102]. The most common histological ﬁndings of
an iCCA are those of an adenocarcinoma showing tubular and/
or papillary structures and a variable ﬁbrous stroma [103–107].
Although it has been proposed that the diagnosis of iCCA can
be made based upon a combination of clinical presentation, lab-
oratory analysis, and radiologic evaluation, pathological diagnosis
is required for deﬁnitive diagnosis in most patients, particularly
those with cirrhosis and small hepatic mass lesions as radio-
graphic studies are nonspeciﬁc [108,109]. Pathological diagnosis
is recommended for all patients who will be undergoing systemic
chemotherapy or radiation therapy, or enrolling in a therapeutic
clinical trial.
The sensitivity of liver biopsy for pathological diagnosis will
depend upon location, size, and operator expertise. Core biopsies
are required for deﬁnitive diagnosis. Although a positive liver
biopsy will establish a diagnosis, a negative biopsy does not
exclude it because of the potential for sampling error. TumorJournal of Hepatology 2014seeding can occur with percutaneous biopsy but the risk is not
well deﬁned.
iCCA needs to be distinguished from benign biliary lesions
such as peribiliary glands, reactive ductular proliferation, biliary
microhamartomas (vonMeyenburg complexes) and bile duct ade-
nomas (peribiliary tract hamartomas), particularly in the presence
of inﬂammation which can result in reactive cellular atypia [110].
The histological appearance of iCCA is similar to that of metastatic
adenocarcinoma arising from extrahepatic primary tumors and
especially those of foregut origin such as lung, pancreas, esopha-
gus, and stomach [110]. The differentiation of iCCA from meta-
static adenocarcinoma cannot be readily ascertained on
histological examination. Differentiation between iCCA andmixed
HCC tumors may require evaluation of speciﬁcmarkers of hepato-
cellular or progenitor cell features such as Hep-Par-1, GPC3,
HSP70, glutamine synthetase, EpCAM, and CK19. CK19 positivity
is not speciﬁc for iCCA. The expression of cytokeratin 7 and cyto-
keratin 20 may be helpful to establish a biliary origin [111,112].
Diagnosis using imaging studies
iCCA may be incidentally detected by cross-sectional imaging
performed for other reasons. Imaging features of iCCA are often
suggestive of the diagnosis but not deﬁnitive enough to obviate
the need for a biopsy. On CT scanning, the typical appearance is
that of a hypodense hepatic mass in the unenhanced phase with
irregular margins, peripheral rim enhancement in the arterial
phase, and progressive hyperattenuation on venous and delayed
phases [113]. CT can also detect the level of biliary obstruction,
capsular retraction or hepatic atrophy. Dynamic CT scanning
can help distinguish between iCCA and HCC. Up to 81% of iCCA
are characterized by a progressive contrast uptake from the arte-
rial to the venous and especially in the delayed phase. This effect
may reﬂect ﬁbrosis which is slow to enhance but retains the
intravenous contrast agent. In contrast, HCC is characterized by
rapid enhancement during the arterial phase and relative wash-
out (hypoattenuation) in the venous or delayed phases. However,
some small mass-forming iCCA are arterially enhancing and may
mimic hepatocellular carcinoma [114,115].
On MRI, iCCA appear hypointense on T1-weighted and hyper-
intense on T2-weighted images [116–118]; T2-weighted images
may also show central hypointensity corresponding to areas of
ﬁbrosis. Dynamic images show peripheral enhancement in the
arterial phase followed by progressive and concentric ﬁlling-in
of the tumor with contrast material. Pooling of contrast on
delayed images is indicative of ﬁbrosis and suggestive of an iCCA
in the right clinical setting. MRI with cholangiopancreatography
(MRI/MRCP) can be helpful to visualize the ductal system and
vascular structures and thereby to determine the anatomic
extent of tumor.
Fluorodeoxyglucose positron emission tomography (FDG-PET
scan) can detect cholangiocarcinomas. Mass forming iCCA as small
as 1 cm can be detected with a reported sensitivity of 85–95%.
However FDG-PET is less useful for inﬁltrating tumors [119–121].
There is limited clinical utility of CT/PET for diagnosis of iCCA in
the liver when CT or MRI imaging has been performed [122].
On ultrasonography, iCCA appears as a hypoechoic mass and
may be associated with peripheral ductal dilatation. These
features are not speciﬁc. Hyperenhancement on contrast
enhanced ultrasound can identify tumors with increased density
of cancer cells but lacks speciﬁcity for iCCA [123,124].vol. 60 j 1268–1289 1275
Recommendations
• Pathological diagnosis is required for a definitive 
diagnosis of iCCA
Recommendation A1
• Pathological diagnosis of iCCA is based on the WHO 
classification for biliary tract cancer. Differentiation 
of metastic adenocarcinoma from primary iCCA 
may require additional clinical and radiological and 
endoscopic evaluation
Recommendation B1
• Immunostaining to detect markers of hepatocellular 
carcinoma (e.g., GPC3, HSP70, and glutamine 
synthetase) or progenitor cell features (e.g., K19, 
EpCAM) is recommended to distinguish iCCA from 
mixed hepatocellular-cholangiocarcinoma tumors if this 
information will change management
Recommendation B1
• A presumed radiographic diagnosis is sufficient in non-
cirrhotic patients in whom a decision has been made to 
proceed with surgical resection
Recommendation B1
• PET-scan is not accurate for early diagnosis of iCCA; its 
role as a staging modality remains controversial
Recommendation B2
• Serological tumor markers such as CA19-9 are 
insensitive for the diagnosis of iCCA and insufficient 
to establish the diagnosis, but may be of prognostic 
significance
Recommendation B1
• Assessment of resectability and/or intra- and 
extrahepatic metastatic disease, as well as venous 
and arterial invasion, is best accomplished using 
radiographic studies such as CT and/or MRI
Recommendation A1
• Future studies should focus on histopathologic features 
and markers to more specifically diagnose and stratify 
iCCA subtypes
Suggestions for future studies
Guidelines
A presumed diagnosis of iCCA can be made on radiological cri-
teria such as venous phase contrast enhancement on dynamic
imaging in the absence of other extrahepatic primary malignan-
cies and cirrhosis. Radiological criteria are insensitive for the
diagnosis of iCCA in the presence of cirrhosis. Radiological studies
cannot reliably differentiate between scirrhous HCC and iCCA, or
metastatic adenocarcinoma and iCCA [125].
Tumor markers
Tumormarkers in serumor bile are not speciﬁc for iCCAbutmay be
of diagnostic value. Current tumor markers such as Carbohydrate
Antigen (CA) 19-9 and carcinoembryonic antigen have signiﬁcant
overlap with other benign diseases and low sensitivity for early
stage disease which limit their use for diagnosis. The sensitivity
and speciﬁcity of CA 19-9 for iCCA is only 62% and 63%, respec-
tively. However, patients with unresectable CCA typically have sig-
niﬁcantly higher CA 19-9 levels compared with patients with
resectable CCA [126]. Other studies have noted that preoperative
CA 19-9 values greater than 100 U/ml were also associated with
worse recurrence-free survival after surgical resection [127]. Bile
duct obstruction or acute cholangitis may affect CA 19-9 levels. In
the setting of bile duct obstruction, CA 19-9 levels should be reas-
sessed after biliary intervention/drainage since the half-life of CA
19-9 is one to three days. Other serum markers, such as serum
cytokeratin-19 fragment (CYFRA 21-1) and CA-242, have been
reported to have higher speciﬁcities than CA 19-9 for iCCA in a lim-
ited number of studies, but are not in routine use [128].
Genetic biomarkers
Recent studies have identiﬁed mRNA and non-coding RNA
expression that are associated with iCCA [61,129–131]. At pres-
ent there is insufﬁcient evidence to support the use of gene test-
ing in blood or tissues for these genes, either singly or in
combination, for the diagnosis of CCA.
Assessment of disease extent
Radiological studies are necessary for assessment of the extent of
local-regional, or distant spread, staging, and resectability. Inva-
sion into the portal vein or hepatic artery, and volumetric assess-
ment of uninvolved liver are important determinants of
resectability. Radiographic studies have a limited ability to deter-
mine the extent of intraductal tumor spread and resectability,
particularly for the periductal inﬁltrative type of iCCA.
Color Doppler duplex US can identify vascular invasion,
encasement, or occlusion of the portal vein and the hepatic
artery. In one report, preoperative US detected 13 of 16 cases of
liver tumors involving the hepatic vein with 81% sensitivity and
97% speciﬁcity, and an 87% positive predictive value [132]. In
another study, preoperative US detected 38 of 41 patients with
CCA and portal vein involvement at surgery, with 93% sensitivity,
99% speciﬁcity, and 97% and 98% positive and negative predictive
values, respectively [133]. These results were comparable to
those found by angiography with computed tomographic arterial
portography which identiﬁed 37 of 41 involved portal veins with
90% sensitivity, 99% speciﬁcity, 95% positive predictive value, and
97% negative predictive value.
FDG-PET cannot be used to diagnose iCCA as any adenocarci-
noma involving the liver may be PET avid, rather the role of1276 Journal of Hepatology 2014FDG-PET is that of a staging modality. The role of FDG-PET in
the management of iCCA, however, is controversial. Mass-forming
iCCA tend to be more FDG avid than other morphological subtypes
[119]. Some data have suggested that the potential beneﬁt of
FDG-PET resides largely in its ability to detect otherwise unsus-
pected metastasis [119,121,134,135]. In fact, FDG-PET was found
to change the surgical management in up to 30% of patients
[119,121,134]. Prior to surgical resection, PET scanning may be con-
sidered to help rule out an occult primary as well as to rule out
otherwise occult metastatic disease.
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Staging systems for iCCA
Traditionally, iCCA has been staged with HCC under the category
of ‘‘primary liver cancers [136].’’ In fact, up until the current 7th
edition of the American Joint Committee on Cancer/International
Union Against Cancer (AJCC/UICCA) staging manual, there was no
distinct internationally recognized staging system for iCCA [137].
There are, however, important epidemiologic, etiologic, and bio-
logic differences between iCCA and HCC [23,138]. As such, there
has been an increasing realization of the importance of establish-
ing a distinct staging system for iCCA [139].
Several staging systems have been proposed for iCCA, with
two staging systems based on data from Japan [140,141]. One
staging system of patients with mass-forming iCCA was based
on multivariate modeling that included 14 clinical and 12 post-
operative surgical and pathological factors. Several independent
factors were associated with worse long-term survival including
presence of vascular invasion, symptomatic disease, regional
lymph node metastasis, and multiple tumors [141]. Based on
these factors, the authors proposed the following staging schema:
Stage 1 disease, solitary tumor without vascular invasion; Stage 2
disease, solitary tumor with vascular invasion; Stage 3a disease,
multiple tumors with or without vascular invasion; Stage 3b dis-
ease, any tumor with regional lymph node metastasis; and Stage
4 disease, iCCA with distant metastasis [141]. Of note, tumor size
was not included as a factor in the staging of patients with iCCA.
A different proposed staging system for iCCA that included tumor
size [140], which stratiﬁed patients based on tumor size of 2 cm
or less vs. more than 2 cm, solitary vs. multiple tumors, and the
presence or absence of hepatic vein, portal vein, or peritoneal
invasion. Each of these factors was assigned a point and the stag-
ing was based on the additive summation of points. Distant
metastasis and regional lymph node metastasis were also
included in a binary fashion (e.g., absent vs. present) [140].
More recently, a large population-based Western cohort of
patients with iCCA was reported, which evaluated the staging
systems proposed by Japanese authors, as well as the 6th edition
of the AJCC/UICCA staging manual [142]. In this study, the
authors noted that each of the previously proposed staging
systems for iCCA performed poorly in their ability to predict
long-term prognosis [142]. While previous studies had reported
conﬂicting results regarding the impact of tumor size on progno-
sis [140,141], they found that tumor size had no effect on sur-
vival, either in overall or in multiple subgroup analyses [142].
The authors also noted that vascular invasion and multiple
tumors had similar effects on prognosis, but the presence of both
factors did not result in worse prognosis. The authors therefore
proposed a simpliﬁed staging system based on the number of
iCCA tumors, vascular invasion, and the presence of metastatic
disease in the regional lymph node basin or at distant sites.
With the recent publication of the 7th edition of the AJCC/UIC-
CA staging manual, there is now a new distinct staging system for
iCCA [137]. The 7th edition AJCC/UICCA staging system largely
reﬂects many of the proposals included in previous publications
[137,142]. Speciﬁcally, tumor size is no longer a prognostic factor,
rather, T-classiﬁcation is based on the number of lesions, vascular
invasion, intrahepatic metastasis, and invasion of adjacent struc-
tures [137]. Speciﬁcally, T1 tumors are solitary without vascular
invasion; T2 disease includes multiple tumors (e.g., multi-focal
disease, satellitosis, intrahepatic metastasis), as well as tumors
associated with any type of vascular invasion (e.g., microvascularJournal of Hepatology 2014or major vascular invasion); T3 tumors directly invade adjacent
structures; and T4 disease includes tumors with any periductal-
inﬁltrating component. As with most other solid liver, biliary,
and gastrointestinal malignancies, AJCC/UICCA staging also
includes both an ‘‘N’’ and ‘‘M’’ sub-classiﬁcation. Regional lymph
node metastasis in the hilar, periduodenal, and peripancreatic
nodes are considered N1 disease, while distant disease is consid-
ered M1 disease.
Although the 7th edition of the AJCC/UICCA is still relatively
new, the validity of the staging system has already been indepen-
dently validated [143]. The authors of the validation study noted
that patients were equally distributed among the AJCC/UICCA 7th
edition stages, which was not the case for the other staging sys-
tems examined. In addition, the 7th edition of the AJCC/UICCA
staging system for iCCA was more discriminating in predicting
survival than the other staging systems evaluated, including the
two Japanese classiﬁcations. There are, however, undoubtedly
limitations to the current 7th edition the staging system for iCCA.
For example, multiple tumors are classiﬁed as T2b. From a clinical
standpoint, it is difﬁcult to distinguish among patients with ‘‘mul-
tiple’’ tumorswho havemulti-focal disease vs. thosewith an index
lesion and intrahepatic metastasis. In addition, the classiﬁcation
of T4 disease needs further validation in future studies that specif-
ically examine the impact of this prognostic factor.
Taken together, while future reﬁnements are likely, the cur-
rent 7th edition AJCC/UICCA staging schema should be the
accepted and preferred staging system for resected iCCA.
Recommendations 5
Recommendations
• The 7th edition of the AJCC/UICCA staging schema 
is currently the preferred staging system for resected 
iCCA
Recommendation B1
• Future studies should focus on stratifying nonsurgical 
patients for clinical studies using a clinical as 
opposed to a surgical staging process. Prognostic 
biomarkers should be explored in the setting of clinical 
investigations
Suggestions for future studiesTreatment
Surgical resection
Surgical resection is the mainstay for treatment of iCCA. As part of
the pre-operative clinical work-up of the patient with possible iCCA,
laboratory exams, including tumor markers such as carcinoembry-
onic antigen (CEA), CA 19-9, and alpha fetoprotein (AFP) should be
obtained. Pre-operative cross-sectional imaging for iCCA should
include either multi-detector, contrast-enhanced helical CT, or
MRI/MRCP as discussed above. On cross-sectional imaging the dis-
tinct morphologic sub-types (i.e., mass-forming, periductal-inﬁltrat-
ing, and intraductal-growth) may have different characteristicsvol. 60 j 1268–1289 1277
Intrahepatic 
disease only
Extrahepatic 
disease
Intrahepatic cholangiocarcinoma (iCCA)
TNM stage I TNM stage II TNM stage III TNM stage IV
Single tumor Single or multinodular
vascular invasion (VI)
Visceral peritoneum perforation,
local hepatic invasion
Periductal invasion, 
N1, M1
Resectable (30-40%)
Curative 
resection
Observation
5-yr survival R0: 40%
5-yr survival N1 and VI: 20%
RF/TACE: median survival 15 mo
Chemotherapy: median survival 12 mo
Local-regional
therapy*
Non-curative 
resection
Enroll in studies of
adjuvant therapy
Gemcitabin and
cisplatin*
Unresectable (60-70%)
Fig. 3. A suggested treatment algorithm for patients with iCCA.⁄ These are standard of practice recommendations. Larger and appropriate studies are required to provide
evidence for standard of care guidelines.
Guidelines[140]. For example, while periductal-inﬁltrating iCCA is often charac-
terized by growth along the bile duct without mass formation, intra-
ductal-growing iCCA may manifest as diffuse and marked duct
ectasia with or without a grossly visible papillary mass or a focal
stricture-like lesion with proximal ductal dilatation [140,144,145].
Overall, the mass-forming type of iCCA is the most common mor-
phological subtype (>85% of cases). Liver function should be thor-
oughly assessed in patients with underlying liver cirrhosis, and
restrictions for resection due to impaired liver function are recom-
mended using criteria recommended for HCC [146].
Data on the role and yield of staging laparoscopy for iCCA are
lacking. Because a subset of patients with biliary malignancies
will have unsuspected metastatic disease, some surgeons have
suggested that staging laparoscopy should be performed at the
time of surgery. The data on the use of laparoscopy in the setting
of resectable iCCA are, however, very limited. In a series of 22
patients with iCCA who underwent diagnostic laparoscopy, 6
patients (27%) who had previously undetected peritoneal or
intrahepatic metastasis were identiﬁed with metastatic disease
[147]. While such reports warrant future validation, currently
there is insufﬁcient evidence to recommend routine staging lap-
aroscopy for patients undergoing surgery for iCCA.
Resection should be undertaken in those patients who are
appropriate surgical candidates and who have potentially resect-
able disease (Fig. 3). Unfortunately, only about 20–40% of patients
with potentially operable disease are offered surgical resection
[148]. This may be due in part to the fact that patients with iCCA
often present with large, locally advanced tumors in need of tech-
nically complex and challenging operations [149]. As with other1278 Journal of Hepatology 2014hepatic malignancies, the goal of surgical resection is to remove
all the disease with negative microscopic (R0) margins while pre-
serving an adequate remnant liver volume. Depending on the size
and location of the iCCA lesion, this may require an extensive
resection including adjacent structures such as the extrahepatic
biliary tree. Extended hepatectomy and/or resection of the extra-
hepatic bile duct bifurcation has been considered necessary in 78%
and 29% of iCCA cases, respectively, in order to obtain an R0 resec-
tion [150]. In another study among patients undergoing resection
of iCCA, 49% of patients required an extended hepatectomy while
21% required a concomitant biliary resection and reconstruction
[151]. In a separate report of one of the largest surgical series pub-
lished to date that included several high volume centers, the
authors noted that 73% of patients required either a hemi-hepa-
tectomy or an extended hepatic resection [149]. Extensive resec-
tions and biliary reconstruction are, therefore, frequently
necessary for patients with iCCA in order to obtain negative
microscopic margins. While perioperative mortality rates are
often reported to be less than 5% in these series [149,151], it is
important to note that these outcomes reﬂect the results from
highly specialized centers. As such, resection of iCCA is probably
best performed at high-volume hepatobiliary centers and patients
should be referred to these centers when resection is being con-
sidered [127,149,152–155].
While removal of clinically suspicious nodal disease is manda-
tory, the role of routine lymphadenectomy is less deﬁned. In
contrast to the practice of many Japanese centers, lymph node dis-
section is not routinely performed at the time of iCCA resection in
most Western countries [156]. In fact, in a large population-basedvol. 60 j 1268–1289
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Western series of patients undergoing resection approximately
one-half of patients had at least one lymph node examined [142].
Of note, however, was the ﬁnding that among patients who
did have lymph nodes examined, metastatic nodal disease was
found in up to 30% of patients [142]. Despite this, some investiga-
tors have argued that routine lymphadenectomy is unnecessary.
For example, in a report on 68 patients with mass-forming iCCA,
36 of who underwent concomitant lymphadenectomy [155], the
authors reported that among those patients without lymph node
involvement, there was no difference in survival or pattern of
recurrence according to the use of lymph node dissection. The
authors concluded that routine lymphadenectomywas not neces-
sary in patients with mass-forming iCCA when lymph node
involvement is not clinically apparent. Other investigators have
noted that N1 status adversely affects overall survival and also
inﬂuences the relative effect of tumor number and vascular inva-
sion on prognosis [149]. Speciﬁcally, in a study encompassing
248 patients with iCCA who underwent lymphadenectomy, 74
(30%) had lymph node metastasis [149]. Lymph node metastasis
was associated with worse median survival; in addition, although
patients with no lymph node metastasis could be stratiﬁed by
tumor number and vascular invasion, among patientswith N1 dis-
ease, multiple tumors and vascular invasion, either alone or
together, failed to discriminate patients into discrete prognostic
groups. In turn, these investigators advocated that routine lym-
phadenectomy should be strongly considered for iCCA as up to
30% of patients will have nodal metastasis and this information
has important prognostic implications. Other investigators,
including the AFC-iCCA-2009 study group, have similarly recom-
mended that routine lymphadenectomy should be performed at
the time of iCCA resection, as lymph node metastasis is more pre-
valent in iCCA than in other tumors that liver surgeonsmaybeused
to dealing with [143]. There is already an established role for
lymph node clearance for other sub-types of hepatobiliary malig-
nancies (e.g., ﬁbrolamellar HCC, gallbladder cancer). Given the
established strong prognostic role of lymph node metastasis for
iCCA, lymphadenectomy should be strongly considered at the time
of surgery.
Outcomes following surgical resection of iCCA remain rela-
tively guarded. Recurrence has been reported to occur in up to
50–60% of patients with a median-disease free survival of
26 months [151,157,158]. Factors associated with an increase in
recurrence include those factors that form the basis of staging
for iCCA: multiple tumors, vascular invasion, and lymph node
metastasis. While the liver is the most common site of recurrence
(e.g., 50–60%), recurrence in regional lymph nodes or the perito-
neum is not uncommon (e.g., 20–25%) [157,158]. A small subset
of patients with liver only recurrence may be candidates for
either ablation or re-resection [151,157,158]. Five-year survival
and overall survival after surgical resection of iCCA ranges from
15% to 40% in most series [127,155,159–161].
There are several factors that are particularly associated with
patient survival, and in turn, need to be consideredwhen selectingTable 3. Trials of adjuvant therapy in BTC.
Study title CI, Location Chemotherapy Numbers
BILCAP Primrose, UK Capecitabine 360
PRODIGE-12 Boucher, France Oxaliplatin-gemcitabine 360
ACTICCAA-1 Arnold, Germany Cisplatin-gemcitabine 280
Journal of Hepatology 2014patients for operative therapy. Several studies have reported that
the presence of metastatic nodal disease is one of the most pow-
erful, independent determinants of survival [149,162]. Speciﬁ-
cally, patients undergoing surgical resection who are found to
have lymph node metastasis have a 5-year survival of less than
20%. It is important to note that most data on the prognostic
implications of lymph node metastasis are derived from surgical
studies, and therefore largely include patients with microscopic
lymph node disease. There is minimal data on the prognosis of
patients with iCCA and clinically positive hilar lymph node dis-
ease that is identiﬁed preoperatively. However, extrapolating
from colorectal data, [163] the prognosis of patients with ‘‘gross’’
hilar adenopathy is particularly poor with few long-term survi-
vors. In addition to lymph node disease, the presence of either
intrahepatic metastasis or major vascular invasion similarly have
a 5-year survival in the range of 20% or less with the vast majority
of patients experiencing a recurrence [149,164]. Given the very
poor prognosis of patients who have clinically evident lymph
node metastasis, intrahepatic metastasis or major vascular inva-
sion, these factors should be considered relatively strong contra-
indications to surgical resection. While surgery may be
warranted in a select subset of patients with these clinical charac-
teristics, decisions about therapy should be made in a multidisci-
plinary setting. Strong consideration should be given to treating
these patients with some type of systemic or loco-regional ther-
apy to allow for a better evaluation of the biology of the disease
prior to any surgical consideration.
For those patients undergoing resection – especially thosewith
N1 disease – adjuvant therapy should be strongly considered.
There have been two randomized studies examining the beneﬁt
of adjuvant therapy following resection. A phase 3 randomized
controlled trial evaluated the beneﬁt of post-operative adjuvant
chemotherapy compared with surgery alone in patients with
resected pancreato-biliary carcinoma [165]. The primary endpoint
was survival and patientswere randomized to receive intravenous
mitomycin C and 5-FU followed by 5-FU orally until disease recur-
rence or surveillance. There appeared to be an improved disease
free survival (20.3% in the treatment group compared with 11.6%
for surveillance) for gallbladder carcinoma (n = 140), but no bene-
ﬁt was found for pancreas adenocarcinoma, CCA (n = 139), or
ampullary cancers; overall, the study was underpowered to prove
a treatment beneﬁt. This is in contrast to the known beneﬁt of
adjuvant treatment in pancreas cancer [166]. A similar random-
ized trial was conducted recruiting a population of CCA, small
bowel, ampullary and peri-ampullary cancers to receive 5-FU or
Gemcitabine [167]. The 96 patients in the CCA group did not
appear to beneﬁt from adjuvant chemotherapy with either drug
but these data are clearly underpowered to support any signiﬁcant
outcome. Table 3 gives a list of current adjuvant studies that
involved randomization of patients to either a speciﬁc treatment
vs. surveillance, in an attempt to address formally the issue of
adjuvant systemic therapy in biliary tract cancer. planned Primary end point Completion of accrual
2 year disease free Q1 2013
Disease free survival Q1 2012
Disease free survival Q1 2015
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Recommendations 6
Recommendations
• Surgical resection is the treatment of choice for iCCA
Recommendation B1 
• Patients with iCCA with single intrahepatic nodules 
and no evidence of disease desemination are optimal 
candidates for resection. Patients demonstrating 
intrahepatic metastases, vascular invasion or obvious 
lymph node metastases should not undergo resection
Recommendation B1
• Staging laparascopy cannot be universally endorsed in 
the staging of iCCA
Recommendation C2
• Lymphadenectomy of regional nodes is recommended 
given its prognostic value
Recommendation B2
• In cirrhotic patients, advanced liver failure precludes 
surgical resection
Recommendation A1
• There is no established adjuvant therapy after resection
Recommendation B1
• Future studies should focus on stratifying patients for 
surgery based on intent to treat, overall survival, and 
incorporating cost-effectiveness analysis
Suggestions for future studiesRecommendations
• LT is not recommended for iCCA or mixed HCC-iCCA 
because results are well below those published for 
standard indications; however, this recommendation 
is based on limited data. LT should only be offered 
in centers with designed clinical research protocols 
employing adjuvant or neoadjuvant therapy
Recommendation B2
• Protocols examining the efficacy of LT for iCCA should 
be limited to lesions without lymphovascular invasion
Recommendation B2
• Future studies should focus on standardized selection 
criteria plus adjuvant and/or neoadjuvant therapy with 
LT as definite therapy for iCCA
Suggestions for future studiesLiver transplantation for iCCA and mixed HCC-iCCA
Liver transplantation (LT) for iCCA is highly controversial. Although
LT for pCCA is well deﬁned in regards to selection criteria, the need
for neoadjuvant therapy and long term outcomes [168], this is not
the case for iCCA. The published data regarding LT for iCCA employs
non-uniform selection criteria, is limited in number of patients
undergoing LT, has disparate neoadjuvant and adjuvant treatment
protocols, and highly variable outcomes. Herein, we will review in
more detail those studies published after the year 2000. An early
study reported a 39% three-year actuarial survival on 16 patients
undergoing LT for iCCA with variable and selective adjuvant che-
motherapy [169]. Univariate analysis performed by combining
pCCAwith the iCCApatients suggested tumor size, invasion of adja-
cent organs, and multiple nodules were poor prognostic variables;
there was an insufﬁcient number of patients for a formal multivar-
iate analysis. Another study reported on LT in 11 patients with iCCA
who received neither adjuvant nor neoadjuvant therapy [170].
Three-year overall survival was 50% with long-term survival
achieved only in those patients with Stage 1 or 2 disease (absence
of lymph node metastases or vascular involvement). The collective
Spanish experience was published on 23 patients with iCCA under-
going LT again in whom 7 received unspeciﬁed adjuvant anti-
cancer therapy [171]. The three-year overall survival was 65%
and perineural invasionwas the only signiﬁcant adverse prognostic
factor in their patient population. Another study reported on 10
patients following LT for iCCA with a three-year overall survival1280 Journal of Hepatology 2014of 50%without speciﬁed anti-cancer therapy [172]. The UCLA group
ﬁrst reported on 25 patients undergoing LT for iCCA in whom 9
underwent adjuvant or neoadjuvant therapy [173]. The adverse
prognostic factors were perineural invasion and multifocality
whereas neoadjuvant plus adjuvant anti-cancer therapy was asso-
ciated with improved long-term survival. Overall survival for the
iCCA was not reported. In a subsequent paper by this group, the
outcome data were modeled to obtain a predictive index [174].
Unfortunately, this analysis grouped iCCA along with pCCA. Seven
predictive features were identiﬁed including multifocality, peri-
neural invasion, inﬁltrative pattern of tumor growth, lack of adju-
vant or neoadjuvant anti-cancer therapy, lymphovascular
invasion, and history of PSC. Patients without adverse prognostic
factors who received anti-cancer therapy had excellent long-term
survival; however, given that iCCA and pCCA were grouped
together it is difﬁcult to dissect how the prognostic index applies
to iCCA. More recently their current protocol has been reviewed
which stratiﬁes patients according to risk of recurrence, employs
neoadjuvant therapy, and advocates assessing the response to neo-
adjuvant therapy in high-risk patients before proceeding on to LT
[175]. In summary, LT for iCCA is not a futile procedure, but the
overall outcomes are suboptimal compared to the 74% ﬁve-year
survival for patients with cirrhosis undergoing LT [176].
As noted above, cirrhosis and viral Hepatitis C and B are risk fac-
tors for iCCA [6], and therefore, the same risk factors which are
well-established for HCC may also predispose the patient to iCCA.
Indeed, certain cancers contain features of both cancers; these
malignancies are referred to as mixed HCC-iCCA. In mixed tumors,
the presence of cholangiocarcinoma elements can be conﬁrmed by
a positive cytokeratin 19 (CK19) and cytokeratin 7 (CK7) staining
by immunohistochemistry. With the recognition that patients can
harbor mixed HCC-iCCA tumors [177,178], a liver biopsy should
be considered for atypical lesions (lesions not diagnostic for HCC
by classical imaging criteria on cross-sectional studies) prior to
LT. Mixed HCC-iCCA lesions have worse outcomes following LT
than patients with HCC [177,178] with a ﬁve-year recurrence rate
of 65% [178]. Such patients should either not undergo transplanta-
tion or be enrolled in research protocols combining adjuvant or
neoadjuvant therapy for iCCA in the transplant setting.
Recommendations 7vol. 60 j 1268–1289
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Loco-regional therapy in the management of iCCA
Althoughmajor hepatectomy is a potentially curative treatment for
iCCA, many patients present with intrahepatic disease beyond the
criteria for resection. For example, resectability rates are generally
quite low and vary among series from 18% to 70% [31,179]. In addi-
tion, many patients do not qualify for resection because of comor-
bidities; these patients may be eligible for loco-regional therapy,
as well as best supportive care. Since the current tumor-node-
metastasis (TNM) staging system for iCCA is based on surgical
acquisition of tissue, this staging system may be inadequate for
evaluating outcomes of loco-regional therapies. An ideal classiﬁca-
tion system for iCCA should therefore not require surgical resection.
Few studies to date have evaluated the evidence-based efﬁ-
cacy of loco-regional treatments in patients with unresectable
iCCA. Loco-regional therapy in these patients may provide symp-
tomatic relief, and might have a positive effect on survival [180].
Loco-regional therapies for patients with unresectable iCCA
include radiation therapy (RT), transarterial chemoembolization
(TACE), transarterial chemoinfusion (TACI), radioembolization
and radiofrequency ablation (RFA). The website www.ClinicalTri-
als.gov lists more than 10 clinical trials of loco-regional therapies
for unresectable iCCA that are currently ongoing or recruiting,
and the outcomes of these trials are awaited.
Radiation therapy
Radiation therapy consists of (i) external-beam RT (EBRT), includ-
ing three dimensional-conformal RT (3D-CRT), intensity-modu-
lated RT (IMRT) and stereotactic body radiotherapy (SBRT), (ii)
brachytherapy, and (iii) proton therapy. The role of EBRT in
patients with unresectable iCCA is not clear. Most studies of RT
have been performed on patients with biliary tract cancer, with
few performed on patients with iCCA. To date, no prospective ran-
domized studies have shown that EBRT beneﬁts these patients,
although several single institution retrospective studies have sug-
gested that EBRT has palliative advantages, including a reduction
in tumor burden and an anecdotal positive effect on survival
[181–183]. One-year survival rates of iCCA patients treated with
EBRT have been found to range from 36.1% to 73% [181–184].
Although tumor control was not generally deﬁned, its rate varied
from 36% to 100%, and grade 3–4 toxicities were infrequent in
these studies. EBRT may completely or partially relieve pain and
obstructive jaundice in patients with unresectable iCCA [181,182].
Although there is no clear evidence for EBRT in the treatment of
iCCA patients, methods such as SBRT may be considered in multi-
disciplinary and adjuvant approaches in the future. A recent retro-
spective analysis of 3839 patients with iCCA from the Surveillance,
Epidemiology, and End Results (SEER) database showed that adju-
vant and deﬁnitive radiation treatment prolonged survival,
although cure rates remained low [185]. The median overall sur-
vival in patients treated with surgery and adjuvant RT, surgery
alone, RT alone, and supportive care alone was 11, 6, 7, and
3 months, respectively. Other retrospective studies also suggest
that adjuvant RT following resection had a survival beneﬁt in iCCA
patients with regional lymph node metastasis [186] and that con-
current EBRT with systemic chemotherapy prolonged progres-
sion-free survival [187]. Moreover, SBRT following chemotherapy
was well tolerated and early local control was promising [188].
There are no data on the use of brachytherapy and proton therapy
for evaluating the outcomes in patients with iCCA.Journal of Hepatology 2014Transarterial chemoembolization (TACE), transarterial
chemoinfusion (TACI), and transarterial radioembolization (TARE)
TACE is the main treatment modality for patients with intermedi-
ate stage HCC not amenable to surgical therapies or local ablation.
The rationale for TACE is that the intra-arterial infusion of a cyto-
toxic agent followed by embolization of the tumor-feeding blood
vessels will result in strong cytotoxic and ischemic effects [189].
Currently, there are two types of TACE procedure, conventional
TACE (cTACE) and drug-eluting bead TACE (debTACE). Because
HCCs are usually hypervascular, TACE may have anti-tumor
effects. Although iCCAs are not overtly hypervascular on CT or
MRI studies, tumor blushes on angiography are frequently identi-
ﬁed in patientswith iCCA [135]. Nonetheless, there have been lim-
ited studies of TACE in iCCA patients and there is an absence of
trials systematically evaluating outcomes with TACE in this popu-
lation [190]. A single-center, retrospective cohort study of 155
patientswith iCCA reported amedian overall survival thatwas sig-
niﬁcantly longer in the patients treated with cTACE group
(12.2 months) than in the non-TACE treated cohort (3.3 months),
and that the tumor control rate in the former group was 89%,
including partial responses in 23% and stable disease in 66%
[191]. A recent meta-analysis of 14 trials of transarterial therapies
in patients with unresectable cholangiocarcinoma found that the
calculatedweighted cumulativemedian overall survival fromdate
of diagnosis was 15.6 ± 1.1 months; 49.8 of all patients had stable
disease by Response Criteria in Solid Tumors (RECIST) criteria
[192]. The survival outcomes of cTACE may be improved by
sequential systemic chemotherapy [193,194]. A retrospective
analysis found that adjuvant cTACE after curative surgery did
not delay recurrence but may prolong the overall survival of
patients with early recurrence [195].
debTACE was developed to improve the anti-tumor activity and
clinical beneﬁts of chemoembolization. The efﬁcacy of debTACE in
patients with iCCA is unclear [196], although a retrospective com-
parative study reported an increase inmedian survival using combi-
nationdebTACEandsystemic chemotherapy (30 months) compared
to those patients treated with systemic chemotherapy alone
(12.7 months) [197]. A recent study found that irinotecan-debTACE
prolonged survival relative to cTACE (11.7 vs. 5.7 months) [198].
Transarterial chemoinfusion (TACI) describes transcatheter
intra-arterial chemotherapy without embolization, which differ-
entiates it from TACE and systemic chemotherapy. The efﬁcacy
of TACI is unclear but retrospective studies reported the favorable
survival outcomes in a small number of patients with unresec-
table iCCA [199–201].
Transarterial radioembolization (TARE) is deﬁned as the infu-
sion of radioactive substances, such as iodine-131 (131I)-labeled
lipiodol or microspheres containing yttrium-90 (90Y) or similar
agents, into the hepatic artery [189]. These transarterially-injected
radioactive substances are delivered tohypervascular tumor-bear-
ing areas, where they emit low-penetration, high-energy radiation
(ß-particles) to tumors. To date, no randomized controlled trials
have compared the efﬁcacy of radioembolization with cTACE or
systemic treatment in patients with unresectable HCC or iCCA.
Several clinical trials of radioembolization in patients with unre-
sectable iCCA are ongoing, and outcomes are awaited. Retrospec-
tive studies have reported that the disease control rates of
radioembolization in patients with iCCA range from 72% to 95%
and that median overall survival ranges from 9.3 to 22 months
[202–204]. Prognostic factors for outcomes included Easternvol. 60 j 1268–1289 1281
Guidelines
Cooperative Oncology Group (ECOG) performance status, tumor
burden, tumor type, portal vein invasion, and tumor response.
Radioembolization was found to be relatively safe, with the most
frequent adverse events being fatigue, abdominal pain, and
increases of serum bilirubin.
Ablation
All guidelines recommend radiofrequency ablation (RFA) as a stan-
dard treatment for patients with small, early stage HCC not suitable
for surgical therapies [146]. There have been few studies of RFA in
patients with iCCA and the outcomes have been less optimal than
those observed with HCC. RFA may provide local control of small,
localized, unresectable lesions with no evidence of extrahepatic
spread [114,115,205–210]. Rates of primary technical effectiveness
and early necrosis of small (6roughly 3.0 cm) tumorswere reported
to be 90–100%. Median overall survival ranged from 33 to
38.5 months, one-year survival rates from 84.6% to 100%, and
three-year survival rates from 43.3% to 83.3%. These ﬁndings sug-
gest that RFA may have survival beneﬁts when compared with
other palliative treatment methods in patients with small, single
iCCA lesions. In patients with local recurrence or residual tumor
after surgery with curative intent, RFA resulted in a median overall
survival of 27.4 to 51 months [114,115,207,211]. Although RFA has
been the most studied, other alternative approaches such as micro-
wave ablation are also feasible [212].
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Recommendations
• There are no established first-line local-regional 
therapeutic options for patients with non-resectable 
iCCA
Recommendation B1
• EBRT cannot be recommended as standard therapy for 
patients with unresectable iCCA. Additional clinical trials 
of single, combination or adjuvant therapy are needed 
to establish its role in this population
Recommendation B2
• TACE and TARE have shown anti-tumor effects with 
acceptable toxicities in patients with iCCA but require 
further examination in appropriately designed clinical 
trials and therefore cannot be recommended as 
standard therapy for patients with unresectable iCCA
Recommendation B2 
• TACI is not recommended for management of patients 
with unresectable iCCA
Recommendation C2 
• Ablation approaches may be considered for small, 
single lesions <3 cm if surgery is not an option, but 
additional clinical trials are needed to establish its role 
in this population
Recommendation C2
• Randomized controlled trials are recommended to 
establish first-line local-regional treatment options for 
patients with unresectable iCCA
Suggestions for future studies1282 Journal of Hepatology 2014Systemic therapy
Trials with systemic therapy for CCA have been fraught with
disease heterogeneity, grouping all patients with biliary tract
cancers into a single disease category. Likewise, as compared
to breast cancer, lung cancer, and even pancreatic cancer the
trials are limited in regards to patient numbers. Thus, any
extrapolation of clinical trial information regarding biliary tract
cancer solely to iCCA is compromised. Therefore, positive data
may be considered a current practice standard from a prag-
matic perspective, but are far too limited to be a ‘‘standard of
care.’’
Systemic therapies
The outcome for patients with advanced and inoperable biliary
tract cancer with treatment compared to best supportive care
has been investigated in two randomized studies [213,214].
Although underpowered, both suggested a beneﬁt for chemo-
therapy with median survivals for those receiving no chemo-
therapy of 2.5–6 months. A comprehensive analysis of 112
clinical trials in advanced biliary tract malignancies have been
published mostly including single arm phase 2 studies [215].
They suggested that Gemcitabine and ﬂuoropyrimidine based
regimens were active but also that the addition of Cisplatin
appeared to add beneﬁt. This is consistent with the published
randomized data (Table 4). These studies in themselves are
not sufﬁciently robust to deﬁne a standard regimen, primarily
because of statistical poverty and some of the difﬁculty in
interpretation is highlighted by a dramatic difference between
the response rates (9–57%) yet a relatively small effect on
survival.The UK ABC studies
Based on the potential efﬁcacy of Gemcitabine and Cisplatin
derived from the unrandomized phase 2 data, the UK NCRN
ABC-01 study compared Cisplatin and Gemcitabine (Cisplatin
25 mg/m2 followed by Gemcitabine 1000 mg/m2, each on days
1 and 8 of a 21-day cycle, CisGem) with Gemcitabine (Gemcita-
bine 1000 mg/m2 on days 1, 8, and 15 of a 28-day cycle) with
6-month progressive free survival (PFS) as the primary endpoint
[216]. It demonstrated improved 6-month PFS in favor of CisGem
compared to Gemcitabine alone (57.1 vs. 45.5%). Consequently,
the study was expanded into a phase 3 study with an identical
protocol except for the primary endpoint which became overall
survival and the addition of quality of life analysis, the UK
advanced biliary cancer 02 (ABC02) study. An additional 324
patients were recruited allowing a pre-planned combined analy-
sis of 410 patients. Median overall survival was 11.7 months for
patients receiving CisGem compared to 8.1 months in patients
receiving Gem alone [217]. Subgroup analysis only including 80
patients with iCCA showed a beneﬁt favoring the combination
arm. Patients receiving CisGem beneﬁted signiﬁcantly and this
regimen has become an international practice standard as well
as the backbone for subsequent studies [217]. These data are sup-
ported by a randomized phase 2 study of 83 patients using the
same protocol [218]. The median overall survival was 11.2 vs.
7.7 months, consistent with the ABC02 data. The ABC02 study
has demonstrated that treatment deﬁning studies can bevol. 60 j 1268–1289
Table 4. Randomized trials in advanced BTC before ABC02.
First author Number of 
patients
Year of 
publication
Survival Chemotherapy [Ref.]
Glimelius 37 1998 6 vs. 2.5 mo 5FU/etoposide vs. BSC [231]
Takada 31 1998 6 vs. 3 mo 5FU/doxorubicin/mitomycin-C vs. BSC [165]
Sharma 87 2010 4.5, 4.6 vs. 9.5 mo BSC, 5FU and oxaliplatin/gemcitabine [214]
Kornek 51 2004 6.7 vs. 9.3 mo Mitomycin-C/gemcitabine vs. mitomycin-C/capecitabine [232]
Ducreux 58 2005 5 vs. 8 mo 5FU vs. cisplatin/5FU [233]
Rao 50 2005 12 vs. 9 mo 5FU/etoposide vs. epirubicin, cisplatin and 5FU [234]
BSC, best supportive care.
JOURNAL OF HEPATOLOGYsuccessfully performed in biliary tract cancers and has stimulated
the international community to improve outcomes.Second line therapies
There are 5 reported studies of second line therapy for biliary
tract cancer. The most robust is a phase 2 study of Gemcitabine
in 32 patients refractory to 5-FU based chemotherapy which
reported a response rate of 7%, stable disease in 21%; a median
time to progression (TTP) of 1.6 months and median survival of
4.1 months. Lower albumin levels (<3.5 g/dl) predicted shorter
survival [219]. A phase 2 study of 5-FU, doxorubicin and mito-
mycin-C (FAM) in 31 patients with pancreas (n = 15) and biliary
tract (n = 16) cancers after Gemcitabine-based chemotherapy
reported a response rate of 13%, stable disease 26%, median
TTP 2.3 months, and survival of 6.7 months [52]. The three
remaining studies are case reports of 6, 4, and 2 patients
respectively from which no conclusions can be drawn. There
is therefore no signiﬁcant evidence that further chemotherapy
beyond progression of ﬁrst-line chemotherapy improves
survival.Biological therapies in biliary tract malignancy
The efﬁcacy of biological therapies in biliary tract cancers has
been mixed. Twenty eight patients were treated with Selumet-
inib, a MEK1/2 inhibitor [220]. Toxicity was manageable and
the disease control rate was 68% with an overall survival of
9.8 months. A different study randomized 150 patients between
a Gemcitabine-Oxaliplatin chemotherapy backbone with or
without the anti-EGFR antibody Cetuximab [221]. The PFS was
5.3 vs. 6 months and overall survival 12 vs. 11 months for the
chemotherapy and combination arms respectively and no phase
3 study is planned. Whether this reﬂects a speciﬁc biliary tract
effect or resembles that which has been found for Oxaliplatin
and Cetuximab combinations in bowel and esophageal cancer
is uncertain. A third study randomized 103 patients between
a Gemcitabine chemotherapy backbone with or without Sorafe-
nib [222]. Disease control and overall survival were not
improved in the Sorafenib group and was associated with sig-
niﬁcantly more toxicity. Translational analysis to deﬁne respon-
sive subgroups is critical to ensure that beneﬁting subgroups
can be identiﬁed.Journal of Hepatology 2014Recommendations 9
Recommendations
• Cisplatin and Gemcitabine is a systemic therapy 
practice standard for iCCA in patients with ECOG 
performance status 0 or 1, but the data are too limited 
to make this an established standard of care
Recommendation B2
• There is no significant evidence that further 
chemotherapy beyond progression of first-line 
chemotherapy improves survival
Recommendation B2
• Randomized controlled trials selecting patients with 
iCCA are urgently needed. Randomized controlled trials 
in which patients with iCCA have sufficient statistical 
power to determine the standard of care are needed
• Further studies should focus on standardized selection 
criteria and comparator arms evaluating systemic 
therapy in homogenous groups of patients with iCCA
• The use of novel molecular strategies to define 
homogenous cohorts within the iCCA population is 
needed
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